Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients
Abstract This study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N = 302...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e60e4dbcc0c64a29898266a634977504 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:e60e4dbcc0c64a29898266a634977504 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:e60e4dbcc0c64a29898266a6349775042021-12-05T12:12:27ZLong-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients10.1038/s41598-021-02659-42045-2322https://doaj.org/article/e60e4dbcc0c64a29898266a6349775042021-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02659-4https://doaj.org/toc/2045-2322Abstract This study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N = 302) or multiple time points (N = 229) 3–12 months after COVID-19 symptom onset or SARS-CoV-2 detection in respiratory specimens was measured by semiquantitative chemiluminescent microparticle immunoassay. The 531 patients (966 specimens) were classified according to the presence or absence of pneumonia symptoms. Anti N IgG was detected in 87.5% of patients (328/375) at 3 months, 38.6% (93/241) at 6 months, 23.7% (49/207) at 9 months, and 26.6% (38/143) at 12 months. The anti-N IgG seropositivity rate was significantly lower at 6, 9, and 12 months than at 3 months (P < 0.01) and was higher in the pneumonia group than in the non-pneumonia/asymptomatic group at 6 months (P < 0.01), 9 months (P = 0.04), and 12 months (P = 0.04). The rate started to decline 6–12 months after symptom onset. Anti-N IgG sample/cutoff index was positively correlated with age (r = 0.192, P < 0.01) but negatively correlated with interval between symptom onset and blood sampling (r = − 0.567, P < 0.01). These findings can guide vaccine strategies in recovered COVID-19 patients.Jira ChansaenrojRitthideach YorsaengNawarat PosuwanJiratchaya PuenpaNasamon WanlapakornNatthinee SudhinarasetManit SripramotePiti ChalongviriyalertSupunee JirajariyavejPhatharaporn KiatpanabhikulJatuporn SaiyarinChulikorn SoudonOrawan ThienfaideeThitisan Palakawong Na AyuthayaChantapat BrukesawanChintana ChirathawornDuangnapa IntharasongkrohDootchai ChaiwanichsiriMila IssarasongkhramRungrueng KitphatiAnek MungaomklangPijaya NagavajaraYong PoovorawanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Jira Chansaenroj Ritthideach Yorsaeng Nawarat Posuwan Jiratchaya Puenpa Nasamon Wanlapakorn Natthinee Sudhinaraset Manit Sripramote Piti Chalongviriyalert Supunee Jirajariyavej Phatharaporn Kiatpanabhikul Jatuporn Saiyarin Chulikorn Soudon Orawan Thienfaidee Thitisan Palakawong Na Ayuthaya Chantapat Brukesawan Chintana Chirathaworn Duangnapa Intharasongkroh Dootchai Chaiwanichsiri Mila Issarasongkhram Rungrueng Kitphati Anek Mungaomklang Pijaya Nagavajara Yong Poovorawan Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients |
description |
Abstract This study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N = 302) or multiple time points (N = 229) 3–12 months after COVID-19 symptom onset or SARS-CoV-2 detection in respiratory specimens was measured by semiquantitative chemiluminescent microparticle immunoassay. The 531 patients (966 specimens) were classified according to the presence or absence of pneumonia symptoms. Anti N IgG was detected in 87.5% of patients (328/375) at 3 months, 38.6% (93/241) at 6 months, 23.7% (49/207) at 9 months, and 26.6% (38/143) at 12 months. The anti-N IgG seropositivity rate was significantly lower at 6, 9, and 12 months than at 3 months (P < 0.01) and was higher in the pneumonia group than in the non-pneumonia/asymptomatic group at 6 months (P < 0.01), 9 months (P = 0.04), and 12 months (P = 0.04). The rate started to decline 6–12 months after symptom onset. Anti-N IgG sample/cutoff index was positively correlated with age (r = 0.192, P < 0.01) but negatively correlated with interval between symptom onset and blood sampling (r = − 0.567, P < 0.01). These findings can guide vaccine strategies in recovered COVID-19 patients. |
format |
article |
author |
Jira Chansaenroj Ritthideach Yorsaeng Nawarat Posuwan Jiratchaya Puenpa Nasamon Wanlapakorn Natthinee Sudhinaraset Manit Sripramote Piti Chalongviriyalert Supunee Jirajariyavej Phatharaporn Kiatpanabhikul Jatuporn Saiyarin Chulikorn Soudon Orawan Thienfaidee Thitisan Palakawong Na Ayuthaya Chantapat Brukesawan Chintana Chirathaworn Duangnapa Intharasongkroh Dootchai Chaiwanichsiri Mila Issarasongkhram Rungrueng Kitphati Anek Mungaomklang Pijaya Nagavajara Yong Poovorawan |
author_facet |
Jira Chansaenroj Ritthideach Yorsaeng Nawarat Posuwan Jiratchaya Puenpa Nasamon Wanlapakorn Natthinee Sudhinaraset Manit Sripramote Piti Chalongviriyalert Supunee Jirajariyavej Phatharaporn Kiatpanabhikul Jatuporn Saiyarin Chulikorn Soudon Orawan Thienfaidee Thitisan Palakawong Na Ayuthaya Chantapat Brukesawan Chintana Chirathaworn Duangnapa Intharasongkroh Dootchai Chaiwanichsiri Mila Issarasongkhram Rungrueng Kitphati Anek Mungaomklang Pijaya Nagavajara Yong Poovorawan |
author_sort |
Jira Chansaenroj |
title |
Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients |
title_short |
Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients |
title_full |
Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients |
title_fullStr |
Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients |
title_full_unstemmed |
Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients |
title_sort |
long-term specific igg response to sars-cov-2 nucleocapsid protein in recovered covid-19 patients |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/e60e4dbcc0c64a29898266a634977504 |
work_keys_str_mv |
AT jirachansaenroj longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT ritthideachyorsaeng longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT nawaratposuwan longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT jiratchayapuenpa longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT nasamonwanlapakorn longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT natthineesudhinaraset longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT manitsripramote longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT pitichalongviriyalert longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT supuneejirajariyavej longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT phatharapornkiatpanabhikul longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT jatupornsaiyarin longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT chulikornsoudon longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT orawanthienfaidee longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT thitisanpalakawongnaayuthaya longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT chantapatbrukesawan longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT chintanachirathaworn longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT duangnapaintharasongkroh longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT dootchaichaiwanichsiri longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT milaissarasongkhram longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT rungruengkitphati longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT anekmungaomklang longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT pijayanagavajara longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients AT yongpoovorawan longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients |
_version_ |
1718372167258734592 |